Cargando…

MiDRMpol: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors

The detection of drug resistance mutations (DRMs) in minor viral populations is of potential clinical importance. However, sophisticated computational infrastructure and competence for analysis of high-throughput sequencing (HTS) data lack at most diagnostic laboratories. Thus, we have proposed a ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aralaguppe, Shambhu G., Ambikan, Anoop T., Ashokkumar, Manickam, Kumar, Milner M., Hanna, Luke Elizabeth, Amogne, Wondwossen, Sönnerborg, Anders, Neogi, Ujjwal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784143/ https://www.ncbi.nlm.nih.gov/pubmed/31480341 http://dx.doi.org/10.3390/v11090806

Ejemplares similares

Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa
por: Siddik, Abu Bakar, et al.
Publicado: (2018)

Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
por: Singh, Kamal, et al.
Publicado: (2019)

Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes
por: Rogers, Leonard, et al.
Publicado: (2018)

Transcriptomics and Targeted Proteomics Analysis to Gain Insights Into the Immune-control Mechanisms of HIV-1 Infected Elite Controllers
por: Zhang, Wang, et al.
Publicado: (2017)

Genome-scale metabolic models for natural and long-term drug-induced viral control in HIV infection
por: Ambikan, Anoop T, et al.
Publicado: (2022)

Distinct lipid profile, low-level inflammation, and increased antioxidant defense signature in HIV-1 elite control status
por: Sperk, Maike, et al.
Publicado: (2021)

Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa
por: Obasa, Adetayo Emmanuel, et al.
Publicado: (2020)

Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs
por: Neogi, Ujjwal, et al.
Publicado: (2020)

Role of myeloid cells in system-level immunometabolic dysregulation during prolonged successful HIV-1 treatment
por: Svensson Akusjärvi, Sara, et al.
Publicado: (2023)

A5 Near full-length HIV-1 genome sequencing in newly diagnosed individuals in Sweden
por: Andersson, E, et al.
Publicado: (2019)

Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa
por: Obasa, Adetayo Emmanuel, et al.
Publicado: (2021)

New onset type 2 diabetes mellitus risks with integrase strand transfer inhibitors-based regimens: A systematic review and meta-analysis
por: Kajogoo, Violet Dismas, et al.
Publicado: (2023)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
por: Rhee, Soo-Yon, et al.
Publicado: (2016)

Integrative proteo-transcriptomic and immunophenotyping signatures of HIV-1 elite control phenotype: A cross-talk between glycolysis and HIF signaling
por: Akusjärvi, Sara Svensson, et al.
Publicado: (2021)

Cis-Allosteric Regulation of HIV-1 Reverse Transcriptase by Integrase
por: Masuda, Takao, et al.
Publicado: (2022)

Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors
por: Singh, Kamalendra, et al.
Publicado: (2014)

Publisher Correction: In vitro replicative fitness of early Transmitted founder HIV-1 variants and sensitivity to Interferon alpha
por: Ashokkumar, Manickam, et al.
Publicado: (2020)

Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa
por: Brado, Dominik, et al.
Publicado: (2018)

Peripheral blood CD4(+)CCR6(+) compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals
por: Svensson Akusjärvi, Sara, et al.
Publicado: (2022)

Author Correction: Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa
por: Brado, Dominik, et al.
Publicado: (2018)

Proteomic landscape of astrocytes and pericytes infected with HIV/SARS-CoV-2 mono/co-infection, impacting on neurological complications
por: Acharya, Arpan, et al.
Publicado: (2023)

Minority Drug-Resistant HIV-1 Variants in Treatment Naïve East-African and Caucasian Patients Detected by Allele-Specific Real-Time PCR
por: Ekici, Halime, et al.
Publicado: (2014)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

Structural coordination between active sites of a CRISPR reverse transcriptase-integrase complex
por: Wang, Joy Y., et al.
Publicado: (2021)

Plasma Metabolic Signature and Abnormalities in HIV-Infected Individuals on Long-Term Successful Antiretroviral Therapy
por: Babu, Hemalatha, et al.
Publicado: (2019)

Characterization of Inducible Transcription and Translation-Competent HIV-1 Using the RNAscope ISH Technology at a Single-Cell Resolution
por: Zhang, Wang, et al.
Publicado: (2018)

Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
por: Winters, Mark A., et al.
Publicado: (2012)

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
por: Siedner, Mark J., et al.
Publicado: (2020)

A Partially Multiplexed HIV Drug Resistance (HIVDR) Assay for Monitoring HIVDR Mutations of the Protease, Reverse-Transcriptase (PRRT), and Integrase (INT)
por: DeVos, Joshua, et al.
Publicado: (2022)

The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance
por: Wainberg, Mark A.
Publicado: (2012)

Coevolutionary Analysis Identifies Protein–Protein Interaction Sites between HIV-1 Reverse Transcriptase and Integrase
por: Hetti Arachchilage, Madara, et al.
Publicado: (2016)

Multi-omics personalized network analyses highlight progressive disruption of central metabolism associated with COVID-19 severity
por: Ambikan, Anoop T., et al.
Publicado: (2022)

Whole-Genome Metagenomic Analysis of the Gut Microbiome in HIV-1-Infected Individuals on Antiretroviral Therapy
por: Bai, Xiangning, et al.
Publicado: (2021)

From Benchtop to Desktop: Important Considerations when Designing Amplicon Sequencing Workflows
por: Murray, Dáithí C., et al.
Publicado: (2015)

rANOMALY: AmplicoN wOrkflow for Microbial community AnaLYsis
por: Theil, Sebastien, et al.
Publicado: (2021)

Can HIV reverse transcriptase activity assay be a low-cost alternative for viral load monitoring in resource-limited settings?
por: Gupta, Soham, et al.
Publicado: (2016)

Coevolved Multidrug-Resistant HIV-1 Protease and Reverse Transcriptase Influences Integrase Drug Susceptibility and Replication Fitness
por: Martin, Supang A., et al.
Publicado: (2021)

Affordable drug resistance genotyping of HIV-1 reverse transcriptase, protease and integrase genes, for resource limited settings
por: Manyana, Sontaga, et al.
Publicado: (2023)

Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy
por: Zhang, Wang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2rkb9gistomnm2cjm70imop5rd